Pharma Likelihood Of Approval
We are the trusted, gold standard intelligence provider to the world’s largest industries
GlobalData powers faster, more informed decisions with:
- Granular industry intelligence: We develop deep, vertical-specific intelligence tailored to your industry, providing 360° insight.
- Exhaustive coverage: We synthesize our vast data universe into formats that support your decision-making needs, covering the sectors, themes, companies and geographies that matter to you.
- Proprietary datasets: We provide you with access to untapped pools of intelligence generated from our proprietary datasets and primary research capabilities.
- Robust methodologies: The quality and timeliness of our data is a key differentiator. We leverage robust research methodologies to turn millions of data points into trusted intelligence.
Thousands of companies, government organizations, and decision makers rely on GlobalData
We have a track record of serving truly diverse clients, including:
- Corporates: From helping the C-suite refine strategy to powering innovation in marketing and R&D, our corporate use cases are endless.
- Investment firms: We help financial analysts develop robust long-term strategies and get alpha signals before the rest.
- Professional services: We give consultants, legal, and accounting firms the critical insights to make faster, more informed decisions.
- Other sectors: From media to academia, we work with sectors as diverse as our data.
The trusted, actionable and future-proof insight you need to stay ahead
We have decades of experience in being the gold standard intelligence provider based on:
- Unique data: Proprietary datasets built from terabytes of data. Our unmatched intelligence gives you true strategic advantage.
- Expert analysis: Leverage collective expertise. Count on our extensive team of researchers, analysts, subject matter experts, and journalists, plus thousands of external thought-leaders.
- Real intelligence over AI: Experience a level of analysis that leaves AI in the dust. Unlock the proprietary datasets unseen by AI and gain a decisive edge.
- Time-saving research solutions: Save hundreds of hours on research. Our comprehensive reports let you focus on delivering actionable insights - not searching for them.
- Unparalleled global coverage: Tap into insights from anywhere. Our extensive global coverage offers an unrivalled view of the market landscape.
- One platform: Access all our unique data, expert analysis, and innovative solutions on one platform.
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model - Nemvaleukin Alfa in Extrahepatic Bile Duct Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Nemvaleukin Alfa in Extrahepatic Bile Duct Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Nemvaleukin Alfa in Extrahepatic Bile Duct Cancer Drug Details:...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model - Cellular Immunotherapy For Liver Fibrosis And Liver Cirrhosis in Liver Cirrhosis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Cellular Immunotherapy For Liver Fibrosis And Liver Cirrhosis in Liver Cirrhosis report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.Cellular Immunotherapy For Liver Fibrosis And...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model - NEO-100 in Meningioma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - NEO-100 in Meningioma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.NEO-100 in MeningiomaDrug Details:NEO-100 is under development for the treatment of glioblastoma multiforme, and...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model - Elraglusib in Ependymoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Elraglusib in Ependymoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Elraglusib in Ependymoma Drug Details: 9-ING41 is under development for the treatment of...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model - Elraglusib in Rhabdomyosarcoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Elraglusib in Rhabdomyosarcoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Elraglusib in Rhabdomyosarcoma Drug Details: 9-ING41 is under development for the treatment of...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model - Elraglusib in Angiosarcoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Elraglusib in Angiosarcoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Elraglusib in Angiosarcoma Drug Details: 9-ING41 is under development for the treatment of...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model - Mirikizumab in Crohn's Disease (Regional Enteritis)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Mirikizumab in Crohn's Disease (Regional Enteritis) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Mirikizumab in Crohn's Disease (Regional Enteritis) Drug Details: Mirikizumab...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model - Darigabat in Panic Disorders
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Darigabat in Panic Disorders report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Darigabat in Panic Disorders Drug Details: Darigabat (CVL-865) is under development for...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model - Tigilanol Tiglate in Soft Tissue Sarcoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Tigilanol Tiglate in Soft Tissue Sarcoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Tigilanol Tiglate in Soft Tissue Sarcoma Drug Details: Tigilanol...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model - Zatolmilast in Traumatic Brain Injury
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Zatolmilast in Traumatic Brain Injury report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.Zatolmilast in Traumatic Brain InjuryDrug Details:BPN-14770 is under development for the treatment...
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.